WallStreetZenWallStreetZen

NASDAQ: CELU
Celularity Inc Stock

$3.21-0.04 (-1.23%)
Updated Jun 14, 2024
CELU Price
$3.21
Fair Value Price
N/A
Market Cap
$62.11M
52 Week Low
$1.59
52 Week High
$8.24
P/E
-0.32x
P/B
2.05x
P/S
2.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.79M
Earnings
-$181.41M
Gross Margin
-25%
Operating Margin
-1,210.73%
Profit Margin
-1,226.7%
Debt to Equity
4.2
Operating Cash Flow
-$64M
Beta
0.54
Next Earnings
Aug 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CELU Overview

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CELU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CELU is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CELU is good value based on its book value relative to its share price (2.05x), compared to the US Biotechnology industry average (6.25x)
P/B vs Industry Valuation
CELU is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CELU due diligence checks available for Premium users.

Be the first to know about important CELU news, forecast changes, insider trades & much more!

CELU News

Valuation

CELU fair value

Fair Value of CELU stock based on Discounted Cash Flow (DCF)
Price
$3.21
Fair Value
-$3.55
Undervalued by
190.54%
CELU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CELU price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.32x
Industry
-10.23x
Market
30.51x

CELU price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.05x
Industry
6.25x
CELU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CELU's financial health

Profit margin

Revenue
$3.8M
Net Income
-$93.9M
Profit Margin
-2,479.6%
CELU's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CELU's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$157.2M
Liabilities
$126.9M
Debt to equity
4.2
CELU's short-term liabilities ($84.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CELU's long-term liabilities ($42.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CELU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.3M
Investing
-$228.0k
Financing
$5.7M
CELU's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CELU vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CELU$62.11M-1.38%-0.32x2.05x
TSBX$62.45M-3.57%-0.29x0.78x
ATRA$61.53M-3.04%-0.24x-0.63x
LVTX$61.52M-2.50%-2.03x1.12x
CDTX$61.31M-5.08%-1.66x-3.45x

Celularity Stock FAQ

What is Celularity's quote symbol?

(NASDAQ: CELU) Celularity trades on the NASDAQ under the ticker symbol CELU. Celularity stock quotes can also be displayed as NASDAQ: CELU.

If you're new to stock investing, here's how to buy Celularity stock.

What is the 52 week high and low for Celularity (NASDAQ: CELU)?

(NASDAQ: CELU) Celularity's 52-week high was $8.24, and its 52-week low was $1.59. It is currently -61.11% from its 52-week high and 101.57% from its 52-week low.

How much is Celularity stock worth today?

(NASDAQ: CELU) Celularity currently has 19,378,164 outstanding shares. With Celularity stock trading at $3.21 per share, the total value of Celularity stock (market capitalization) is $62.11M.

Celularity stock was originally listed at a price of $100.60 in May 21, 2019. If you had invested in Celularity stock at $100.60, your return over the last 5 years would have been -96.81%, for an annualized return of -49.81% (not including any dividends or dividend reinvestments).

How much is Celularity's stock price per share?

(NASDAQ: CELU) Celularity stock price per share is $3.21 today (as of Jun 14, 2024).

What is Celularity's Market Cap?

(NASDAQ: CELU) Celularity's market cap is $62.11M, as of Jun 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Celularity's market cap is calculated by multiplying CELU's current stock price of $3.21 by CELU's total outstanding shares of 19,378,164.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.